Moderna and Merck announced mRNA-4157/V940, in combination with KEYTRUDA, demonstrated a 44% reduction in the risk of disease recurrence or death in melanoma patients
Revenue from operations for the half year was Rs. 178.5 crore, declined by 23% whereas net profit for the half year was Rs. 16.9 crore, declined by 70%
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
Agreement strengthens Evonik’s track record as leading contract development and manufacturing organization (CDMO)
Transformation to pure-play Innovative Medicines company nears completion
.jpg)
Evonik's six innovation growth fields are: Sustainable nutrition, healthcare solutions, advanced food ingredients, membranes, cosmetic solutions, and additive manufacturing
Evonik in association with Remondis has opened its first plant in India to ensure Zero Liquid Discharge. It is located at Dombivli in Western Maharashtra
The DalPhos ligands were developed by Prof. Mark Stradiotto and his research team at the Department of Chemistry, Dalhousie University
#BeTheChangeForTB is a public awareness initiative under the Corporate TB Pledge and aims to create a cadre of Youth Changemakers who can act as catalysts of change to help eliminate TB from India
The phosphine ligand is available on the kilo scale for the first time, providing scientists with a powerful solution for cross-coupling chemistry
Subscribe To Our Newsletter & Stay Updated
